We are live on
!
Find out more
FCM
Farallon Capital Management Portfolio holdings
AUM
$21.7B
1-Year Est. Return
79.24%
This Fund
S&P 500
This Quarter
Est. Return
-0.07%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$19.1B
AUM Growth
-$4.04B
(-17%)
Cap. Flow
-$3.24B
Cap. Flow
% of AUM
-16.98%
Top 10 Holdings %
Top 10 Hldgs %
50.33%
Holding
204
New
48
Increased
30
Reduced
30
Closed
31
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
EA
Electronic Arts
EA
|
+$492M |
| 2 |
Broadcom
AVGO
|
+$292M |
| 3 |
KKR & Co
KKR
|
+$280M |
| 4 |
Roivant Sciences
ROIV
|
+$248M |
| 5 |
Mastercard
MA
|
+$138M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
EXAS
Exact Sciences
EXAS
|
+$650M |
| 2 |
CYBR
CyberArk
CYBR
|
+$470M |
| 3 |
Salesforce
CRM
|
+$334M |
| 4 |
Nasdaq
NDAQ
|
+$290M |
| 5 |
RNAM
Avidity Biosciences
RNAM
|
+$233M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.53% |
| 2 | Communication Services | 11.31% |
| 3 | Financials | 11.23% |
| 4 | Technology | 10.28% |
| 5 | Consumer Discretionary | 4.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BBNX
51
Beta Bionics
BBNX
$790M
| $36.2M | 0.19% |
3,607,920
-706,000
| -16% | -$10.4M |
|
52
Assembly Biosciences
ASMB
$653M
| $34.1M | 0.18% |
1,227,590
| – | – |
|
|
JOYY
53
JOYY Inc
JOYY
$3.68B
| $33.8M | 0.18% |
578,200
| – | – |
|
54
NetEase
NTES
$80.1B
| $32.6M | 0.17% |
+291,219
| New | +$36.1M |
|
|
NVO
55
Novo Nordisk
NVO
$201B
| $28.7M | 0.15% |
+782,000
| New | +$37.1M |
|
|
BITW
56
Bitwise 10 Crypto Index ETF
BITW
$604M
| $26.9M | 0.14% |
603,000
-2,782,500
| -82% | -$141M |
|
|
PCSC
57
DELISTED
Perceptive Capital Solutions
PCSC
| $24.7M | 0.13% |
2,250,000
| – | – |
|
58
Royalty Pharma
RPRX
$26.1B
| $23.6M | 0.12% |
+493,000
| New | +$21.6M |
|
59
Minerva Neurosciences
NERV
$219M
| $14.2M | 0.07% |
2,365,000
| – | – |
|
60
Ceco Environmental
CECO
$4.66B
| $13.9M | 0.07% |
+234,000
| New | +$15.1M |
|
61
Avalo Therapeutics
AVTX
$1.05B
| $13.7M | 0.07% |
+916,000
| New | +$14.3M |
|
62
CALL
CG Oncology
CGON
$6.65B
| $13.5M | 0.07% |
+200,000
| New | +$11.3M |
|
63
GDS Holdings
GDS
$6.89B
| $11.8M | 0.06% |
+292,000
| New | +$12.5M |
|
|
MAZE
64
Maze Therapeutics
MAZE
$1.51B
| $11.1M | 0.06% |
+373,000
| New | +$16.5M |
|
65
Teva Pharmaceuticals
TEVA
$42.8B
| $10.7M | 0.06% |
354,000
+314,000
| +785% | +$10.1M |
|
66
FormFactor
FORM
$10.3B
| $5.48M | 0.03% |
+56,500
| New | +$4.86M |
|
67
MasTec
MTZ
$23.9B
| $5.47M | 0.03% |
+17,000
| New | +$4.6M |
|
68
Entegris
ENTG
$24.7B
| $5.33M | 0.03% |
+45,500
| New | +$5.38M |
|
69
Citigroup
C
$234B
| $5.33M | 0.03% |
+47,000
| New | +$5.35M |
|
|
VNET
70
VNET Group
VNET
$2.16B
| $5.23M | 0.03% |
623,347
-5,662,039
| -90% | -$60M |
|
71
Hyatt Hotels
H
$17.1B
| $5.18M | 0.03% |
+36,000
| New | +$5.71M |
|
72
Western Alliance Bancorporation
WAL
$8.98B
| $5.17M | 0.03% |
+73,000
| New | +$6.08M |
|
73
Timken Company
TKR
$9.25B
| $5.13M | 0.03% |
+51,000
| New | +$5.07M |
|
74
Flex
FLEX
$46.6B
| $5.11M | 0.03% |
+78,000
| New | +$4.99M |
|
75
S&P Global
SPGI
$123B
| $5.1M | 0.03% |
+12,000
| New | +$5.57M |
|
Similar funds
VARA
PCM
BPA
NAM
ASRS
Farallon Capital Management's Q1 2026 Portfolio in Review
As of Q1 2026, Farallon Capital Management held 204 positions worth $19.1B, down 17% from $23.1B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Farallon Capital Management withdrew a net $3.24B in Q1 2026, closing 31 positions and reducing 30 holdings. Its most notable exit was Exact Sciences, an estimated $650M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 41% a quarter earlier, followed by Communication Services and Financials.
Against the trend, Farallon Capital Management opened a new position in Dianthus Therapeutics worth $70.2M.
- Farallon Capital Management's largest Q1 2026 buy was Dianthus Therapeutics: 836,000 shares worth $70.2M.
- Farallon Capital Management added most to Electronic Arts in Q1 2026, an estimated $492M increase.
- Farallon Capital Management's biggest Q1 2026 reduction was Wabtec, cutting an estimated $210M.
- Farallon Capital Management fully exited Exact Sciences in Q1 2026, selling an estimated $650M.
- Farallon Capital Management's ten largest holdings make up 50% of its $19.1B portfolio in Q1 2026.
- Farallon Capital Management opened 48 new positions and closed 31 in Q1 2026.
- Farallon Capital Management's portfolio value fell 17% quarter-over-quarter to $19.1B.
Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.